The American Journal of Therapeutics, a renowned bi-monthly medical journal covering pharmacology and therapeutics, recommends that ivermectin be used routinely to curb the COVID-19, also known as the Chinese Communist Party (CCP) Virus, Lifesitenews reported.
In an article titled “Review of emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19,” researchers found large and statistically significant reductions in mortality and recovery time, in addition to “significantly reduced risks of contracting COVID -19 with regular use of ivermectin.”
Ivermectin is a semi-synthetic drug commonly used to treat lice, scabies, ascariasis, and other parasitic infections, which is also very inexpensive and readily available.
Although this drug has been shown in several research studies to be effective against coronavirus, it has suffered from major smear campaigns, as has hydroxychloroquine. For this reason, many doctors do not dare to recommend it, and many people do not dare to take it as an alternative.
Also, this drug has been subject to censorship on Youtube and Facebook for “violating policies,” labeling the contents that explain its benefits as “medical disinformation” and because it can “mislead people.”
However, there is increasing evidence of its efficacy; for example, this new publication concludes that there are “ivermectin distribution campaigns leading to a rapid decrease in morbidity and mortality across the population,” leading them to conclude that, as an oral agent, ivermectin is “effective at all stages of COVID-19”.
So how many deaths could have been avoided?
The U.S. Food and Drug Administration (FDA) continues to warn U.S. consumers that ivermectin should not be used to treat or prevent COVID-19.
Like the Center for Disease Control and Prevention (CDC), the FDA seeks to establish policies that follow the vaccine agenda as the only solution to contain the virus. Big pharma has huge profits and a vested interest in seeing this agenda fulfilled, including inoculating people of all ages, repeating doses every year. So is an inexpensive dewormer a threat to these interests?
According to the authors of the publication, since 2012, multiple in vitro studies have shown that ivermectin inhibits the replication of many viruses, including influenza, Zika, dengue, and others.
Among other benefits, ivermectin inhibits replication and binding of SARS-CoV-2 to host tissue through several observed and proposed mechanisms.
In addition, it prevents the transmission and development of COVID-19 disease in people exposed to infected patients.
Not only that, but ivermectin leads to temporally associated reductions in the case of fatality rates in regions following ivermectin distribution campaigns.
On the other hand, the researchers found that ivermectin’s safety, availability, and cost are a major advantage. Side effects are mild and rare, as observed in nearly 40 years of use and billions of doses administered.
“In the context of ivermectin’s long-standing safety record, low cost, and wide availability along with the consistent, reproducible, large magnitude of findings on transmission rates, need for hospitalization, and mortality, widespread deployment in both prevention and treatment has been proposed,” note the authors.
“Based on the totality of the trials and epidemiologic evidence presented in this review,” they conclude: “ivermectin should be globally and systematically deployed in the prevention and treatment of COVID-19.”
A bit of history
Ivermectin was first discovered in the 1960s by Satoshi Omura, a microbiologist at the Kitasato Institute in Tokyo, and William Campbell, an American biologist and parasitologist who, at the time, was working at Merck Research Labs in New Jersey.
As part of the research agreement between the institute and Merck, Omura isolated microorganisms from soil samples collected in Japan and conducted a preliminary evaluation of their bioactivities in hopes of discovering a new antiparasitic.
Promising samples were then sent to Campbell’s laboratory in the U.S. for further testing. Among those Campbell received from Omura was a single soil sample containing a potent unknown compound later named avermectin.
To improve avermectin’s safety and biological activity, scientists chemically modified the compound to produce the popular antiparasitic known today as ivermectin.
First introduced as a commercial product for use in animals in 1981, ivermectin proved useful against a wide range of parasites, including lungworms, mites, lice, intestinal worms, and ticks.
Next, Australian researchers found that ivermectin exerts potent anti-viral effects against two viruses that cause life-threatening human diseases, human immunodeficiency virus-1 (HIV-1) and dengue virus (DENV).
Ivermectin has also been found to limit infection by other viral pathogens, such as the Venezuelan equine encephalitis virus and influenza virus.
Because of these reports, other researchers committed to the real welfare of people decided to test the activity of ivermectin against the CCHP virus.
If more and more people dare to take this step, a substantial change in the health care industry may soon be achieved.